Journal ArticleDOI
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik,Steven Shak,Gong Tang,Chungyeul Kim,Joffre B. Baker,Maureen T. Cronin,Frederick L. Baehner,Michael G. Walker,Drew Watson,Taesung Park,William Hiller,Edwin R. Fisher,D. Lawrence Wickerham,John Bryant,Norman Wolmark +14 more
Reads0
Chats0
TLDR
The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.Abstract:
background The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor–positive tumors is poorly defined by clinical and histopathological measures. methods We tested whether the results of a reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancerrelated genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient. results Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan–Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P<0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P<0.001). The recurrence score was also predictive of overall survival (P<0.001) and could be used as a continuous function to predict distant recurrence in individual patients. conclusions The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor–positive breast cancer.read more
Citations
More filters
Journal ArticleDOI
A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.
Jordan M. Winter,Laura H. Tang,David S. Klimstra,Murray F. Brennan,Jonathan R. Brody,Flavio G. Rocha,Xiaoyu Jia,Li-Xuan Qin,Michael I. D’Angelica,Ronald P. DeMatteo,Yuman Fong,William R. Jarnagin,Eileen M. O'Reilly,Peter J. Allen +13 more
TL;DR: MUC1 and MSLN were superior to pathologic features and other putative biomarkers as predicting survival group and Molecular assays comparing cancers from short and long survivors are an effective strategy to screen biomarkers and prioritize candidate cancer genes for diagnostic and therapeutic studies.
Journal ArticleDOI
Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative
Christian Brueffer,Johan Vallon-Christersson,Dorthe Grabau,Anna Ehinger,Jari Häkkinen,Cecilia Hegardt,Janne Malina,Yilun Chen,Pär-Ola Bendahl,Jonas Manjer,Martin Malmberg,Christer Larsson,Niklas Loman,Lisa Rydén,Åke Borg,Lao H. Saal +15 more
TL;DR: In this paper, the authors developed classifiers for five conventional biomarkers (estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), Ki67, and Nottingham histologic grade (NHG) based on tumor mRNA sequencing (RNA-seq).
Journal ArticleDOI
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Ian J. Majewski,René Bernards +1 more
TL;DR: The genomic technologies that can be used to develop drug response indicators, or biomarkers, are reviewed and hurdles in their development and the implementation of biomarkers in clinical practice are discussed.
Journal ArticleDOI
The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California.
Marilyn L. Kwan,Christine B. Ambrosone,Marion M. Lee,Janice Barlow,Sarah E. Krathwohl,Isaac J. Ergas,Christine H. Ashley,Julie R. Bittner,Jeanne Darbinian,Keren Stronach,Bette J. Caan,Warren Davis,Susan E. Kutner,Charles P. Quesenberry,Carol P. Somkin,Barbara Sternfeld,John K. Wiencke,Shichun Zheng,Lawrence H. Kushi +18 more
TL;DR: The Pathways Study will become a rich resource to examine behavioral and molecular factors and breast cancer prognosis, including Pathways, a prospective study of women with breast cancer in Kaiser Permanente Northern California.
Journal ArticleDOI
Breast-tissue sampling for risk assessment and prevention
TL;DR: Ductal lavage, RPFNA and random and directed core needle biopsies are all being utilized in ongoing multi-institutional Phase II studies, and the strengths and weaknesses of each method are reviewed.
References
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
Todd R. Golub,Todd R. Golub,Donna K. Slonim,Pablo Tamayo,Christine Huard,Michelle Gaasenbeek,Jill P. Mesirov,Hilary A. Coller,Mignon L. Loh,James R. Downing,Michael A. Caligiuri,Clara D. Bloomfield,Eric S. Lander +12 more
TL;DR: A generic approach to cancer classification based on gene expression monitoring by DNA microarrays is described and applied to human acute leukemias as a test case and suggests a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge.
Journal ArticleDOI
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie,Charles M. Perou,Robert Tibshirani,Turid Aas,Stephanie Geisler,Hilde Johnsen,Trevor Hastie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,T. Thorsen,Hanne Quist,John C. Matese,Patrick O. Brown,David Botstein,Per Eystein Lønning,Anne Lise Børresen-Dale +16 more
TL;DR: Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Journal ArticleDOI
Quantitative monitoring of gene expression patterns with a complementary DNA microarray.
TL;DR: A high-capacity system was developed to monitor the expression of many genes in parallel by means of simultaneous, two-color fluorescence hybridization, which enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA.
Journal ArticleDOI
Gene expression profiling predicts clinical outcome of breast cancer
Laura J. van't Veer,Hongyue Dai,Marc J. van de Vijver,Yudong D. He,Augustinus A. M. Hart,Mao Mao,Hans Peterse,Karin van der Kooy,Matthew J. Marton,Anke T. Witteveen,George J. Schreiber,Ron M. Kerkhoven,Christopher J. Roberts,Peter S. Linsley,René Bernards,Stephen H. Friend +15 more
TL;DR: DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.
Related Papers (5)
Gene expression profiling predicts clinical outcome of breast cancer
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver,Yudong D. He,Laura J. van't Veer,Hongyue Dai,Augustinus A. M. Hart,D.W. Voskuil,George J. Schreiber,Johannes L. Peterse,Christopher J. Roberts,Matthew J. Marton,Mark Parrish,Douwe Atsma,Anke T. Witteveen,Annuska M. Glas,Leonie J. M. J. Delahaye,Tony van de Velde,Harry Bartelink,Sjoerd Rodenhuis,Emiel J. Th. Rutgers,Stephen H. Friend,René Bernards +20 more
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more